Evidence map›Paper›PMID 32425949›Full record

ReviewFrontiers in immunology2020

Nanoparticle-Based Immunoengineered Approaches for Combating HIV.

Allan Bowen, Elizabeth E Sweeney, Rohan Fernandes

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Nanosystems Applied to HIV Infection: Prevention and Treatments.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Allan BowenThe George Washington Cancer Center, The George Washington University, Washington, DC, United States.
Elizabeth E SweeneyThe George Washington Cancer Center, The George Washington University, Washington, DC, United States.
Rohan FernandesThe George Washington Cancer Center, The George Washington University, Washington, DC, United States.

Funding

Biomaterials-Enhanced NK Cells for Improved Elimination of the HIV ReservoirR21AI136102 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI CRUZ, CONRAD RUSSELL YOUNG, FERNANDES, ROHAN · 2018 to 2019
$435k
NIAID NIH HHS R21 AI136102
6 · The paper itself

Abstract

Highly active antiretroviral therapy (HAART) serves as an effective strategy to combat HIV infections by suppressing viral replication in patients with HIV/AIDS. However, HAART does not provide HIV/AIDS patients with a sterilizing or functional cure, and introduces several deleterious comorbidities. Moreover, the virus is able to persist within latent reservoirs, both undetected by the immune system and unaffected by HAART, increasing the risk of a viral rebound. The field of immunoengineering, which utilizes varied bioengineering approaches to interact with the immune system and potentiate its therapeutic effects against HIV, is being increasingly investigated in HIV cure research. In particular, nanoparticle-based immunoengineered approaches are especially attractive because they offer advantages including the improved delivery and functionality of classical HIV drugs such as antiretrovirals and experimental drugs such as latency-reversing agents (LRAs), among others. Here, we present and discuss the current state of the field in nanoparticle-based immunoengineering approaches for an HIV cure. Specifically, we discuss nanoparticle-based methods for improving HAART as well as latency reversal, developing vaccines, targeting viral fusion, enhancing gene editing approaches, improving adoptively transferred immune-cell mediated reservoir clearance, and other therapeutic and prevention approaches. Although nanoparticle-based immunoengineered approaches are currently at the stage of preclinical testing, the promising findings obtained in these studies demonstrate the potential of this emerging field for developing an HIV cure.

Indexed as

NanoparticlesAdoptive TransferAIDS VaccinesAnimalsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBioengineeringCD4-Positive T-LymphocytesDrug Delivery SystemsGene EditingHIV-1HIV InfectionsHumansMiceVirus LatencyVirus ReplicationAIDS VaccinesAnti-HIV Agentscombination therapy for HIVHAART (highly active antiretroviral therapy)HIV cure strategiesimmune activationimmunoengineeringlatency reversing agentsnanoparticles

Identifiers

PMID32425949
PMCPMC7212361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.